SOPHiA GENETICS (NASDAQ:SOPH) Price Target Raised to $9.00 at BTIG Research

SOPHiA GENETICS (NASDAQ:SOPH) had its price target hoisted by equities researchers at BTIG Research from $8.00 to $9.00 in a research report issued on Wednesday, Marketbeat Ratings reports. The firm currently has a “buy” rating on the stock. BTIG Research’s price objective would suggest a potential upside of 31.58% from the stock’s previous close.

Several other equities analysts also recently commented on SOPH. Zacks Research raised shares of SOPHiA GENETICS to a “hold” rating in a research note on Tuesday, July 21st. Weiss Ratings restated a “sell (d-)” rating on shares of SOPHiA GENETICS in a report on Friday, July 17th. Finally, HC Wainwright upped their price target on SOPHiA GENETICS from $12.00 to $14.00 and gave the company a “buy” rating in a research report on Wednesday. Three analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, SOPHiA GENETICS presently has a consensus rating of “Hold” and an average price target of $10.00.

SOPHiA GENETICS Price Performance

Shares of SOPHiA GENETICS stock opened at $6.84 on Wednesday. The company has a fifty day moving average of $5.52 and a 200-day moving average of $5.11. SOPHiA GENETICS has a 52-week low of $2.92 and a 52-week high of $6.98. The stock has a market capitalization of $573.81 million, a price-to-earnings ratio of -13.15 and a beta of 0.96. The company has a debt-to-equity ratio of 1.05, a quick ratio of 1.90 and a current ratio of 2.06.

SOPHiA GENETICS (NASDAQ:SOPH) last issued its earnings results on Tuesday, August 4th. The company reported ($0.26) EPS for the quarter, missing the consensus estimate of ($0.21) by ($0.05). SOPHiA GENETICS had a negative return on equity of 62.74% and a negative net margin of 44.48%.The firm had revenue of $23.31 million during the quarter, compared to analysts’ expectations of $21.72 million. Equities research analysts expect that SOPHiA GENETICS will post -0.58 EPS for the current year.

Insider Activity

In related news, Chairman Jurgi Camblong sold 20,000 shares of the stock in a transaction dated Tuesday, July 21st. The shares were sold at an average price of $6.63, for a total value of $132,600.00. Following the sale, the chairman directly owned 3,492,822 shares of the company’s stock, valued at $23,157,409.86. This represents a 0.57% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Ross Muken sold 9,838 shares of the firm’s stock in a transaction dated Monday, July 6th. The stock was sold at an average price of $5.22, for a total transaction of $51,354.36. Following the completion of the sale, the chief executive officer directly owned 670,651 shares of the company’s stock, valued at approximately $3,500,798.22. The trade was a 1.45% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold a total of 221,092 shares of company stock worth $1,250,070 over the last 90 days. Insiders own 4.88% of the company’s stock.

Institutional Trading of SOPHiA GENETICS

Several institutional investors and hedge funds have recently modified their holdings of SOPH. Perkins Capital Management Inc. purchased a new stake in shares of SOPHiA GENETICS in the 4th quarter worth $49,000. Squarepoint Ops LLC bought a new position in shares of SOPHiA GENETICS during the 3rd quarter worth $49,000. First Dallas Securities Inc. purchased a new position in shares of SOPHiA GENETICS during the first quarter valued at $50,000. Quadrature Capital Ltd purchased a new position in shares of SOPHiA GENETICS during the fourth quarter valued at $54,000. Finally, XTX Topco Ltd bought a new stake in shares of SOPHiA GENETICS in the fourth quarter valued at about $55,000. Institutional investors own 31.59% of the company’s stock.

Trending Headlines about SOPHiA GENETICS

Here are the key news stories impacting SOPHiA GENETICS this week:

• Positive Sentiment: Raised 2026 outlook: SOPHiA GENETICS increased its full-year revenue guidance to $94 million-$96 million, representing 22%-24% year-over-year growth and exceeding the approximately $93.4 million analyst consensus. Management also expects to reach adjusted EBITDA breakeven by year-end, an important milestone for the currently loss-making company. SOPHiA GENETICS 2026 outlook
• Positive Sentiment: Revenue beat and improving EBITDA: Second-quarter revenue rose 27% year over year to $23.3 million, ahead of the $21.7 million consensus estimate. The adjusted EBITDA loss narrowed 27% to $8.8 million, indicating progress toward profitability. SOPHiA GENETICS Q2 2026 results
• Positive Sentiment: AstraZeneca partnership: The company entered a multiyear global collaboration with AstraZeneca to develop, validate, and deploy two companion diagnostics for precision-oncology therapies. The agreement could expand SOPHiA’s role in pharmaceutical development and commercial testing, although financial terms were not disclosed. SOPHiA GENETICS AstraZeneca collaboration
• Negative Sentiment: Bottom-line miss: SOPHiA GENETICS reported a second-quarter loss of $0.26 per share, worse than the $0.21 consensus estimate. Net loss remained elevated at $22.4 million, while reported and adjusted gross margins declined from the prior-year period. SOPHiA GENETICS earnings report

SOPHiA GENETICS Company Profile

SOPHiA GENETICS SA is a data-driven medicine company founded in 2011 and headquartered in La Tène, Switzerland. The firm develops and operates a cloud-native software platform designed to standardize and analyze complex genomic and radiomic data. Its core offering, the SOPHiA DDM™ platform, leverages artificial intelligence and machine learning algorithms to help healthcare institutions, laboratories and biopharmaceutical partners derive actionable insights from next-generation sequencing and medical imaging datasets.

The SOPHiA DDM™ platform supports a range of clinical applications, including oncology, hereditary diseases and rare genetic disorders.